Citius Oncology Inc (NASDAQ:CTOR) shares, rose in value on Friday, July 11, with the stock price down by -13.23% to the previous day’s close as strong demand from buyers drove the stock to $2.82.
Actively observing the price movement in the last trading, the stock closed the session at $3.25, falling within a range of $2.82 and $3.185. The value of beta (5-year monthly) was -0.063. Referring to stock’s 52-week performance, its high was $49.00, and the low was $0.55. On the whole, CTOR has fluctuated by 120.31% over the past month.
With the market capitalization of Citius Oncology Inc currently standing at about $201.78 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CTOR’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of CTOR currently trading nearly -13.64% and 50.74% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.59, while the 7-day volatility ratio is showing 19.40% which for the 30-day chart, stands at 27.46%. Furthermore, Citius Oncology Inc (CTOR)’s beta value is 3.12.
A comparison of Citius Oncology Inc (CTOR) with its peers suggests the former has fared considerably weaker in the market. CTOR showed an intraday change of -13.23% in last session, and over the past year, it grew by 145.22%%.
Data on historical trading for Citius Oncology Inc (NASDAQ:CTOR) indicates that the trading volumes over the past 10 days have averaged 1.81 and over the past 3 months, they’ve averaged 1.15 million. According to company’s latest data on outstanding shares, there are 71.55 million shares outstanding.
Nearly 95.08% of Citius Oncology Inc’s shares belong to company insiders and institutional investors own 0.15% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.11 million shares as on 2025-06-13, resulting in a short ratio of 0.17. According to the data, the short interest in Citius Oncology Inc (CTOR) stood at 206.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 47100.0. The stock has fallen by -75.18% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CTOR stock heading into the next quarter.
